RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors
NCT06545201
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
30
Enrollment
OTHER_GOV
Sponsor class
Conditions
KRAS G12V
T Cell Therapy
Interventions
BIOLOGICAL:
RE001 T cell
Sponsor
Henan Cancer Hospital